Month: April 2025

A WOMAN has shared what happened to her once she had stopped taking fats jabs. As a growing number of people and celebrities share their epic Mounjaro transformations, mum-of-three Mary has revealed what’s happened to her ever since she went cold turkey. tiktok/@contrary_mary1Mum-of-three Mary took to TikTok where she revealed what’s happened to her body … Read more

The success of drugs such as Ozempic, Wegovy, and Zepbound has sparked a race among pharmaceutical labs worldwide. These medications are based on compounds originally developed for type 2 diabetes but have taken off as weight loss treatments. Orforglipron. U.S. drugmaker Eli Lilly announced that its new treatment, orforglipron, has completed the third phase of … Read more

Related Stocks: NAS:LEXX, NAS:LEXXW,

In its continuing war against copycat drugs, Eli Lilly (LLY) said on Wednesday that it filed suits against four telehealth companies that offer cheaper versions of its blockbuster GLP-1 weight loss drugs Mounjaro and Zepbound. Read more…

Becker’s asked C-suite executives from hospitals and health systems across the U.S. to share the biggest healthcare questions for 2025. The 34 executives featured in this article are all speaking at the Becker’s Healthcare 13th Annual CEO+CFO Roundtable on Nov. 3-6, 2025 at the Hilton Chicago. To learn more about this event, click here. If … Read more

Eli Lilly (NYSE: LLY) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a weight loss medicine that’s already generating more than $1 billion in quarterly sales, although it was approved only in late 2023. Zepbound’s prospects still look bright, but some recent developments point … Read more

DUBLIN–(BUSINESS WIRE)–The “Incretin-based Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034” report has been added to ResearchAndMarkets.com’s offering. The Incretin-based Drugs Market was valued at USD 37.4 billion in 2024, and is projected to reach USD 68.7 billion by 2034, rising at a CAGR of 6.3%. The market is categorized by drug … Read more

Eli Lilly Sues 4 GLP-1 Telehealth Startups, Escalating War on Knockoff Drugs  WIRED Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro  CNBC Lilly sues four compounders over copies of weight-loss drugs  Reuters Eli Lilly sues Houston-based compounding pharmacy over alleged ‘knockoff’ obesity, diabetes drugs  Houston Public Media Eli Lilly opens a new legal front in its battle … Read more

Related Stocks: LEXX,